FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991466811> ?p ?o ?g. }

• W1991466811 endingPage "1075" @default.
• W1991466811 startingPage "1071" @default.
• W1991466811 abstract "High-dose melphalan with autologous stem cell support improves survival as part of initial therapy for myeloma. Previous studies of pre-transplant induction regimens have compared paraprotein response rates but not long-term outcomes after transplant. We reviewed the records of all patients with multiple myeloma who received an autologous stem cell transplant at the University of Pennsylvania Medical Center. We compared outcomes for 69 patients who received high-dose melphalan conditioning after January 1, 2003 as part of initial therapy for myeloma, including 41 patients who received anthracycline-based induction (VAD or DVD) and 28 patients who received thalidomide and dexamethasone induction. Baseline characteristics in these two groups were not different, though potentially clinically important differences were apparent in assignment to post-transplant consolidation and maintenance therapy. Despite similar response rates during induction therapy, thalidomide and dexamethasone induction was associated with better progression-free survival (hazard ratio 0.18, P = 0.011) after transplant. This effect persisted in multivariable regression models including baseline characteristics and post-transplant treatment. Overall survival was not different between the two groups. These results suggest that the use of thalidomide during induction therapy may lead to improved long-term outcomes after transplant. Future trials comparing induction therapies should examine progression-free and overall survival after transplant to confirm this benefit. Am. J. Hematol., 2007. © 2007 Wiley-Liss, Inc." @default.
• W1991466811 created "2016-06-24" @default.
• W1991466811 creator A5006502393 @default.
• W1991466811 creator A5008423046 @default.
• W1991466811 creator A5014838335 @default.
• W1991466811 creator A5015896987 @default.
• W1991466811 creator A5016205416 @default.
• W1991466811 creator A5025991750 @default.
• W1991466811 creator A5029801761 @default.
• W1991466811 creator A5037460404 @default.
• W1991466811 creator A5038738545 @default.
• W1991466811 creator A5041561013 @default.
• W1991466811 creator A5041976525 @default.
• W1991466811 creator A5043871151 @default.
• W1991466811 creator A5047973111 @default.
• W1991466811 creator A5053542677 @default.
• W1991466811 creator A5068715900 @default.
• W1991466811 creator A5080630441 @default.
• W1991466811 creator A5088286702 @default.
• W1991466811 date "2007-01-01" @default.
• W1991466811 modified "2023-09-26" @default.
• W1991466811 title "Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support" @default.
• W1991466811 cites W1840931904 @default.
• W1991466811 cites W1978377409 @default.
• W1991466811 cites W2010766702 @default.
• W1991466811 cites W2024961946 @default.
• W1991466811 cites W2064006160 @default.
• W1991466811 cites W2082997526 @default.
• W1991466811 cites W2093757149 @default.
• W1991466811 cites W2102591890 @default.
• W1991466811 cites W2146607984 @default.
• W1991466811 cites W2148188974 @default.
• W1991466811 cites W2158040196 @default.
• W1991466811 cites W2163129932 @default.
• W1991466811 cites W3145716452 @default.
• W1991466811 cites W4236730981 @default.
• W1991466811 cites W4376542883 @default.
• W1991466811 doi "https://doi.org/10.1002/ajh.21038" @default.
• W1991466811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17696204" @default.
• W1991466811 hasPublicationYear "2007" @default.
• W1991466811 type Work @default.
• W1991466811 sameAs 1991466811 @default.
• W1991466811 citedByCount "16" @default.
• W1991466811 countsByYear W19914668112012 @default.
• W1991466811 countsByYear W19914668112013 @default.
• W1991466811 countsByYear W19914668112014 @default.
• W1991466811 countsByYear W19914668112016 @default.
• W1991466811 countsByYear W19914668112021 @default.
• W1991466811 countsByYear W19914668112022 @default.
• W1991466811 crossrefType "journal-article" @default.
• W1991466811 hasAuthorship W1991466811A5006502393 @default.
• W1991466811 hasAuthorship W1991466811A5008423046 @default.
• W1991466811 hasAuthorship W1991466811A5014838335 @default.
• W1991466811 hasAuthorship W1991466811A5015896987 @default.
• W1991466811 hasAuthorship W1991466811A5016205416 @default.
• W1991466811 hasAuthorship W1991466811A5025991750 @default.
• W1991466811 hasAuthorship W1991466811A5029801761 @default.
• W1991466811 hasAuthorship W1991466811A5037460404 @default.
• W1991466811 hasAuthorship W1991466811A5038738545 @default.
• W1991466811 hasAuthorship W1991466811A5041561013 @default.
• W1991466811 hasAuthorship W1991466811A5041976525 @default.
• W1991466811 hasAuthorship W1991466811A5043871151 @default.
• W1991466811 hasAuthorship W1991466811A5047973111 @default.
• W1991466811 hasAuthorship W1991466811A5053542677 @default.
• W1991466811 hasAuthorship W1991466811A5068715900 @default.
• W1991466811 hasAuthorship W1991466811A5080630441 @default.
• W1991466811 hasAuthorship W1991466811A5088286702 @default.
• W1991466811 hasBestOaLocation W19914668111 @default.
• W1991466811 hasConcept C126322002 @default.
• W1991466811 hasConcept C141071460 @default.
• W1991466811 hasConcept C143998085 @default.
• W1991466811 hasConcept C207103383 @default.
• W1991466811 hasConcept C2776364478 @default.
• W1991466811 hasConcept C2776611710 @default.
• W1991466811 hasConcept C2776694085 @default.
• W1991466811 hasConcept C2776755627 @default.
• W1991466811 hasConcept C2778684742 @default.
• W1991466811 hasConcept C2779050716 @default.
• W1991466811 hasConcept C2779429289 @default.
• W1991466811 hasConcept C2779609412 @default.
• W1991466811 hasConcept C2780401358 @default.
• W1991466811 hasConcept C2911091166 @default.
• W1991466811 hasConcept C44249647 @default.
• W1991466811 hasConcept C71924100 @default.
• W1991466811 hasConceptScore W1991466811C126322002 @default.
• W1991466811 hasConceptScore W1991466811C141071460 @default.
• W1991466811 hasConceptScore W1991466811C143998085 @default.
• W1991466811 hasConceptScore W1991466811C207103383 @default.
• W1991466811 hasConceptScore W1991466811C2776364478 @default.
• W1991466811 hasConceptScore W1991466811C2776611710 @default.
• W1991466811 hasConceptScore W1991466811C2776694085 @default.
• W1991466811 hasConceptScore W1991466811C2776755627 @default.
• W1991466811 hasConceptScore W1991466811C2778684742 @default.
• W1991466811 hasConceptScore W1991466811C2779050716 @default.
• W1991466811 hasConceptScore W1991466811C2779429289 @default.
• W1991466811 hasConceptScore W1991466811C2779609412 @default.
• W1991466811 hasConceptScore W1991466811C2780401358 @default.
• W1991466811 hasConceptScore W1991466811C2911091166 @default.

• next